TY - JOUR
T1 - Low-dose combination therapy
T2 - The rationalization for an ACE inhibitor and a calcium channel blocker in higher risk patients
AU - Kaplan, Norman M
N1 - Funding Information:
This supplement was supported in part by an educational grant from Novartis Pharmaceuticals Corporation, East Hanover, NJ.
PY - 2001
Y1 - 2001
N2 - As more high-risk hypertensives are treated and the need for more intensive antihypertensive therapy is recognized, combination therapies are increasingly used. For initial therapy, particularly for relatively low-risk patients, low-dose combinations are often appropriate. For those who require additional therapy, higher doses of combinations may provide further efficacy while minimizing dose-dependent side effects of monotherapy, thereby improving adherence to therapy. Those combination agents should provide 24-h control with one daily dose, thereby ensuring protection in the early morning hours. Combining an angiotensin converting enzyme inhibitor and a calcium channel blocker is a rational approach to treating hypertension. Not only does it provide significantly better blood pressure control than individual components used as monotherapy, it also minimizes dose-dependent side effects. Also, combining agents from different classes results in complementary mechanisms of action that provide other cardiovascular protective benefits.
AB - As more high-risk hypertensives are treated and the need for more intensive antihypertensive therapy is recognized, combination therapies are increasingly used. For initial therapy, particularly for relatively low-risk patients, low-dose combinations are often appropriate. For those who require additional therapy, higher doses of combinations may provide further efficacy while minimizing dose-dependent side effects of monotherapy, thereby improving adherence to therapy. Those combination agents should provide 24-h control with one daily dose, thereby ensuring protection in the early morning hours. Combining an angiotensin converting enzyme inhibitor and a calcium channel blocker is a rational approach to treating hypertension. Not only does it provide significantly better blood pressure control than individual components used as monotherapy, it also minimizes dose-dependent side effects. Also, combining agents from different classes results in complementary mechanisms of action that provide other cardiovascular protective benefits.
KW - Angiotensin converting enzyme inhibitors
KW - Antihypertension therapy
KW - Calcium channel blockers
UR - http://www.scopus.com/inward/record.url?scp=0035002475&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035002475&partnerID=8YFLogxK
U2 - 10.1016/s0895-7061(01)01315-2
DO - 10.1016/s0895-7061(01)01315-2
M3 - Article
C2 - 11370959
AN - SCOPUS:0035002475
SN - 0895-7061
VL - 14
SP - 8S-11S
JO - American Journal of Hypertension
JF - American Journal of Hypertension
IS - 5 II
ER -